Ser308
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.1.1
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser308  -  GATA3 (human)

Site Information
IKPkRRLsAARRAGT   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 456464

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 1 , 2 ) , mutation of modification site ( 1 , 2 , 3 ) , phospho-antibody ( 2 ) , western blotting ( 1 , 2 )
Disease tissue studied:
breast cancer ( 2 , 3 ) , breast ductal carcinoma ( 2 ) , colorectal cancer ( 1 ) , colorectal carcinoma ( 1 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
PKACA (human) ( 2 , 3 )
Treatments:
bortezomib ( 2 ) , H-89 ( 2 ) , medroxyprogesterone ( 2 ) , mPKI ( 2 )

Downstream Regulation
Effects of modification on GATA3:
activity, induced ( 3 ) , protein degradation ( 2 )
Effects of modification on biological processes:
cell growth, induced ( 2 ) , transcription, induced ( 1 , 3 )
Induce interaction with:
DNA ( 1 )

Disease / Diagnostics Relevance
Relevant diseases:
breast cancer ( 2 )

References 

1

Liu H, et al. (2017) Interleukin-4 and interleukin-13 increase NADPH oxidase 1-related proliferation of human colon cancer cells. Oncotarget 8, 38113-38135
28498822   Curated Info

2

Izzo F, et al. (2014) Progesterone receptor activation downregulates GATA3 by transcriptional repression and increased protein turnover promoting breast tumor growth. Breast Cancer Res 16, 491
25479686   Curated Info

3

Bouchard MF, Taniguchi H, Viger RS (2005) Protein kinase A-dependent synergism between GATA factors and the nuclear receptor, liver receptor homolog-1, regulates human aromatase (CYP19) PII promoter activity in breast cancer cells. Endocrinology 146, 4905-16
16109788   Curated Info